Plant Name: Thalictrum glaucum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.808E-12 | 8.292E-09 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, NQO2, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.074E-11 | 1.185E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.319E-09 | 3.157E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.351E-08 | 1.634E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.958E-08 | 2.030E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NQO2, PTGS1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.922E-08 | 3.416E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 3.629E-07 | 2.608E-04 | APP, CA12, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.027E-07 | 2.740E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 4.609E-07 | 2.867E-04 | APP, CA2, CYP1A2, HIF1A, MAOB, PTGS2, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.737E-07 | 3.668E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.367E-07 | 3.913E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.127E-06 | 5.707E-04 | CA2, CA7, HIF1A, HTT, PIK3CB, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 1.736E-06 | 8.590E-04 | APP, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, TP53 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.889E-06 | 9.140E-04 | APP, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.993E-33 | 1.523E-28 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.162E-25 | 3.442E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.332E-06 | 1.058E-03 | PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.412E-06 | 1.884E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.989E-06 | 2.871E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.086E-05 | 4.078E-03 | APP, CA2, CA9, CYP1A2, ESR1, MAOB, PTGS2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.958E-05 | 6.990E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.197E-24 | 5.007E-20 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.254E-32 | 7.567E-30 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.615E-10 | 1.582E-08 | CYP2C9; APP; MAOB; MAOA; CYP2C19; PTGS2; PTGS1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.510E-10 | 3.029E-08 | CYP2C9; MAOB; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.516E-08 | 2.878E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.346E-07 | 3.258E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19; PTGS2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.314E-07 | 1.677E-05 | PIK3CA; PIK3CB; TP53; ESR1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.431E-06 | 2.473E-05 | PIK3CA; PIK3CB; PTGS2; PTGS1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.159E-06 | 3.266E-05 | CYP2C9; CYP2C19; PTGS2; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.952E-06 | 3.968E-05 | PIK3CA; PIK3CB; TP53; HIF1A |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.189E-05 | 1.308E-04 | PIK3CA; PIK3CB; TP53; HIF1A; ESR1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 8.018E-06 | 9.702E-05 | PIK3CA; PIK3CB; PTGS2; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.001E-05 | 6.915E-04 | PIK3CA; PIK3CB; TP53 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.898E-05 | 2.922E-04 | MAOB; MAOA; CYP1A2 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.405E-05 | 5.961E-04 | PIK3CA; PIK3CB; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 9.837E-05 | 7.534E-04 | PIK3CA; PIK3CB; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.034E-04 | 7.534E-04 | PIK3CA; PIK3CB; PTGS2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.249E-04 | 7.534E-04 | PIK3CA; PIK3CB; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.085E-04 | 7.534E-04 | PIK3CA; PIK3CB; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.844E-04 | 1.307E-03 | PIK3CA; PIK3CB; PTGS2; HIF1A; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.308E-04 | 7.534E-04 | PIK3CA; PIK3CB; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.308E-04 | 7.534E-04 | PIK3CA; PIK3CB; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.249E-04 | 7.534E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.625E-04 | 8.541E-04 | PIK3CA; PIK3CB; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.694E-04 | 8.541E-04 | PIK3CA; PIK3CB; ESR1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.638E-04 | 1.502E-03 | CYP2C9; MAOB; MAOA; CYP1A2; PTGS2; CYP2C19; CYP3A4; PTGS1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.765E-04 | 8.541E-04 | PIK3CA; PIK3CB; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.170E-04 | 1.370E-03 | PIK3CA; PIK3CB; TP53 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.765E-04 | 8.541E-04 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.723E-04 | 1.502E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.335E-04 | 1.692E-03 | PIK3CA; PIK3CB; ESR1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.596E-04 | 1.738E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.868E-04 | 1.785E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.898E-04 | 1.983E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 7.598E-04 | 2.419E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 7.972E-04 | 2.473E-03 | PIK3CA; PIK3CB; PTGS1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.187E-03 | 3.419E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.598E-04 | 2.419E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.092E-03 | 3.222E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.024E-03 | 3.096E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.339E-03 | 3.682E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.679E-03 | 4.323E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.371E-03 | 7.647E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.514E-03 | 7.730E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.661E-03 | 1.279E-02 | PIK3CA; PIK3CB; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 9.785E-03 | 1.675E-02 | PIK3CA; PTGS2; TP53 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 9.455E-03 | 1.658E-02 | PIK3CA; PIK3CB |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 4.659E-03 | 9.721E-03 | PIK3CA; PIK3CB |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.002E-02 | 1.684E-02 | PIK3CA; PIK3CB |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 9.455E-03 | 1.658E-02 | PIK3CA; PIK3CB |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.419E-02 | 2.146E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 8.550E-03 | 1.567E-02 | PIK3CA; PIK3CB |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 7.518E-03 | 1.400E-02 | PIK3CA; PIK3CB |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.350E-03 | 1.061E-02 | PIK3CA; PIK3CB |
| hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 9.455E-03 | 1.658E-02 | PIK3CA; PIK3CB |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 4.527E-03 | 9.609E-03 | MAOB; MAOA |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.298E-03 | 7.647E-03 | PIK3CA; PIK3CB |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.139E-03 | 8.943E-03 | PIK3CA; PIK3CB |
| hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 5.069E-03 | 1.022E-02 | PIK3CA; PIK3CB |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 9.829E-03 | 1.675E-02 | PIK3CA; PIK3CB |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.200E-02 | 1.886E-02 | PIK3CA; PIK3CB |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.099E-02 | 1.773E-02 | PIK3CA; PIK3CB |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.060E-02 | 1.733E-02 | PIK3CA; PIK3CB |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.159E-02 | 1.845E-02 | PIK3CA; PIK3CB |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 6.086E-03 | 1.188E-02 | PIK3CA; PIK3CB |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.060E-02 | 1.733E-02 | PIK3CA; PIK3CB |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.348E-02 | 2.065E-02 | PIK3CA; PIK3CB |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.667E-02 | 2.430E-02 | PIK3CA; PIK3CB |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.481E-02 | 2.212E-02 | PIK3CA; PIK3CB |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.596E-02 | 2.355E-02 | MAOB; MAOA |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.691E-02 | 2.435E-02 | PIK3CA; PIK3CB |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.069E-03 | 1.022E-02 | CA2; CYP3A4 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.739E-02 | 2.475E-02 | PIK3CA; PIK3CB |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.348E-02 | 2.065E-02 | PIK3CA; PIK3CB |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.912E-02 | 2.659E-02 | PIK3CA; PIK3CB |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.963E-02 | 2.699E-02 | PIK3CA; PIK3CB |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.837E-02 | 2.584E-02 | PIK3CA; PIK3CB |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.145E-02 | 2.884E-02 | PIK3CA; PIK3CB |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.066E-02 | 2.809E-02 | PIK3CA; PIK3CB |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.334E-02 | 3.104E-02 | PIK3CA; PIK3CB |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.821E-02 | 3.670E-02 | PIK3CA; PIK3CB |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 2.941E-02 | 3.785E-02 | MAOB; MAOA |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 3.376E-02 | 4.256E-02 | HTT; TP53 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.587E-02 | 3.403E-02 | PIK3CA; PIK3CB |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.971E-02 | 4.809E-02 | PIK3CA; PIK3CB |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.669E-02 | 4.530E-02 | PIK3CA; PIK3CB |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.187E-02 | 4.059E-02 | PIK3CA; PIK3CB |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 4.074E-02 | 4.881E-02 | PIK3CA; PIK3CB |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.570E-02 | 4.454E-02 | PIK3CA; PIK3CB |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.351E-03 | 5.804E-03 | PIK3CA; PIK3CB |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.413E-03 | 7.647E-03 | CYP1A2; CYP3A4 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.448E-03 | 5.925E-03 | MAOB; MAOA |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 2.548E-03 | 6.045E-03 | MAOB; MAOA |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.069E-03 | 5.215E-03 | PIK3CA; PIK3CB |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.557E-03 | 4.187E-03 | PIK3CA; PIK3CB |
| hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 1.638E-03 | 4.307E-03 | MAOB; MAOA |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.255E-03 | 3.531E-03 | MAOB; MAOA |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.396E-04 | 1.920E-03 | CA2; CA4 |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 2.917E-04 | 1.307E-03 | MAOB; MAOA |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 5.881E-04 | 1.983E-03 | MAOB; MAOA |
| hsa04966 | Collecting duct acid secretion_Homo sapiens_hsa04966 | 3.975E-02 | 4.809E-02 | CA2 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.478E-03 | 1.400E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; MAOA; PTGS1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAOB |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; PIK3CA; PIK3CB; CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; MAOB; MAOA; APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| NA: NA | Edema | NA | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PIK3CA |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; PTGS1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOB; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOB; MAOA; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOB; MAOB; MAOA |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| NA: NA | Motor symptoms | NA | MAOB |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A2; MAOB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOB; MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PTGS1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; SLC6A2; PTGS1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; MAOB |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAOB |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; HIF1A; TP53; PIK3CA; PIK3CB; CA1; CA9; ESR1; ESR1; NQO2; APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAOB |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1; NQO2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |